Literature DB >> 6865897

Correlation of structure and activity in ansamycins. Molecular structure of sodium rifamycin SV.

S K Arora.   

Abstract

The crystal and molecular structure of the sodium salt of rifamycin SV (clinically known as rifacin) as the monohydrate ethanol solvate has been determined to study the conformation of the ansa chain in unsubstituted rifamycins and also to clarify the metal complexation with rifamycins. The crystals belong to the space group P2(1)2(1)2(1) with cell dimensions (estimated standard deviations in parentheses) of a = 12.061 (2), b = 13.936 (2), and c = 24.731 (4) A. The structure was solved by direct methods and refined to an R factor of 0.069. The conformation of the ansa chain differs from that of other active rifamycins, e.g., rifampcin and rifamycin B at the joining point of the ansa chain to the naphthohydroquinone chromophore. The conformation of the middle part of the ansa chain, which is essential for activity against DNA-dependent RNA polymerase, remains the same. The sodium ion is penta-coordinated and has a trigonal bipyramidal geometry. The intermolecular hydrogen bonding involves O(9), O(10), O(5), and O(6) through water and ethanol molecules. A two-step mode of action of rifamycins has been postulated, and the conformations of antibiotics suitable for penetration of the membrane barrier and that for antibiotic-enzyme complex formation have been suggested.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6865897

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  6 in total

1.  Effect of topical rifamycin SV treatment on cyclosporin A blood levels in a renal transplant recipient.

Authors:  E Renoult; J Hubert; P Trechot; D Hestin; M Kessler; J L'Hermite
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

Review 3.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

4.  Conformational variety for the ansa chain of rifamycins: comparison of observed crystal structures and molecular dynamics simulations.

Authors:  A Bacchi; G Pelizzi
Journal:  J Comput Aided Mol Des       Date:  1999-07       Impact factor: 3.686

5.  Structural, functional, and genetic analysis of sorangicin inhibition of bacterial RNA polymerase.

Authors:  Elizabeth A Campbell; Olga Pavlova; Nikolay Zenkin; Fred Leon; Herbert Irschik; Rolf Jansen; Konstantin Severinov; Seth A Darst
Journal:  EMBO J       Date:  2005-02-03       Impact factor: 11.598

Review 6.  Antiviral therapy in human immunodeficiency virus infection.

Authors:  E Sandström
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.